We are live on ! Find out more
APM

Avidity Partners Management Portfolio holdings

AUM $936M
1-Year Est. Return 195%
This Fund
S&P 500
This Quarter Est. Return
+42.53%
1 Year Est. Return
+195%
3 Year Est. Return
+460.87%
5 Year Est. Return
+815.5%
10 Year Est. Return
–
AUM
$3.08B
AUM Growth
+$924M
Cap. Flow
+$456M
Cap. Flow %
14.8%
Top 10 Hldgs %
38.34%
Holding
121
New
53
Increased
26
Reduced
7
Closed
25

Top Buys

Rank Stock Value
1
AZN icon
AstraZeneca
AZN
+$122M
2
LLY icon
Eli Lilly
LLY
+$121M
3
MRVI icon
Maravai LifeSciences
MRVI
+$96M
4
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$78.7M
5
AVTR icon
Avantor
AVTR
+$51.7M

Top Sells

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$104M
2
MRK icon
Merck
MRK
+$94.9M
3
BIIB icon
Biogen
BIIB
+$81.3M
4
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$67.1M
5
TMO icon
Thermo Fisher Scientific
TMO
+$52.2M

Sector Composition

Rank Sector Weight
1 Healthcare 91.07%
2 Technology 1.87%
3 Financials 0.18%
4 Industrials 0.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DVAX
51
DELISTED
Dynavax Technologies
DVAX
$17.8M 0.58%
4,000,000
+1,975,000
+98% +$8.94M
BLU
52
DELISTED
BELLUS Health Inc.
BLU
$17.5M 0.57%
+5,726,000
New +$15.5M
KNSA icon
53
Kiniksa Pharmaceuticals
KNSA
$6.23B
$17.1M 0.55%
+965,300
New +$17M
NTLA icon
54
Intellia Therapeutics
NTLA
$1.51B
$16.5M 0.54%
+303,000
New +$11M
ALPN
55
DELISTED
Alpine Immune Sciences Inc
ALPN
$15.7M 0.51%
1,248,000
+438,000
+54% +$4.3M
RETA
56
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$15.5M 0.5%
+125,690
New +$16.5M
SGRY icon
57
Surgery Partners
SGRY
$2.15B
$15.4M 0.5%
+531,000
New +$13.2M
CERT icon
58
Certara
CERT
$1.26B
$13.6M 0.44%
+404,663
New +$14.8M
STRO icon
59
Sutro Biopharma
STRO
$386M
$13.6M 0.44%
+62,600
New +$10.4M
CDXS icon
60
Codexis
CDXS
$158M
$13.1M 0.43%
+600,000
New +$9.88M
HARP
61
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$13M 0.42%
78,500
-38,670
-33% -$5.98M
OLMA icon
62
Olema Pharmaceuticals
OLMA
$977M
$13M 0.42%
+270,000
New +$12.7M
ONCS
63
DELISTED
OncoSec Medical Incorporated
ONCS
$12.6M 0.41%
+88,727
New +$9.46M
KURA icon
64
Kura Oncology
KURA
$793M
$11.4M 0.37%
+347,645
New +$12.2M
TSHA icon
65
Taysha Gene Therapies
TSHA
$1.61B
$10.4M 0.34%
392,000
– –
CSTL icon
66
Castle Biosciences
CSTL
$742M
$10.1M 0.33%
+150,000
New +$8.13M
ALDX icon
67
Aldeyra Therapeutics
ALDX
$97.1M
$9.84M 0.32%
1,435,000
+5,000
+0.3% +$35.1K
SCYX icon
68
SCYNEXIS
SCYX
$37.4M
$9.6M 0.31%
+156,875
New +$7.35M
OSH
69
DELISTED
Oak Street Health, Inc.
OSH
$9.17M 0.3%
150,000
+50,000
+50% +$2.62M
GRTS
70
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$8.36M 0.27%
+2,122,064
New +$6.42M
VSPRU
71
DELISTED
Vesper Healthcare Acquisition Corp. Unit
VSPRU
$7.27M 0.24%
600,000
– –
IGMS
72
DELISTED
IGM Biosciences
IGMS
$7.06M 0.23%
+80,000
New +$5.62M
LGND icon
73
Ligand Pharmaceuticals
LGND
$5.77B
$6.18M 0.2%
+99,546
New +$5.68M
COGT icon
74
Cogent Biosciences
COGT
$6.76B
$5.84M 0.19%
+519,645
New +$5.71M
OM icon
75
Outset Medical
OM
$86.4M
$5.68M 0.18%
6,667
– –
1 2
3
4 5

Similar funds

NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
PWAM
Private Wealth Asset Management Cedar Rapids, Iowa $935M AUM 17.66% 1-Year Est. Return
LJAC
L.J. Altfest & Co New York $935M AUM 27.19% 1-Year Est. Return
NI
NetEase Inc Hangzhou, China $934M AUM 11.31% 1-Year Est. Return
MCM
Massar Capital Management Stamford, Connecticut $934M AUM 14.18% 1-Year Est. Return
TS
Tamar Securities Woodland Hills, California $934M AUM 26.74% 1-Year Est. Return
TW
TritonPoint Wealth Chevy Chase, Maryland $934M AUM 23.95% 1-Year Est. Return
PGA
Portland Global Advisors Portland, Maine $938M AUM 13.22% 1-Year Est. Return

Avidity Partners Management's Q4 2020 Portfolio in Review

As of Q4 2020, Avidity Partners Management held 121 positions worth $3.08B, up 43% from $2.16B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Avidity Partners Management deployed $456M of net new capital in Q4 2020, opening 53 new positions and adding to 26 existing holdings. Its largest new stake was AstraZeneca: 1,150,000 shares worth $115M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, up from 80% a quarter earlier, followed by Technology and Financials.

On the sell side, the largest reduction was Biohaven Pharmaceutical Holding Company Ltd., an estimated $67.1M trimmed.

  • Avidity Partners Management's largest Q4 2020 buy was AstraZeneca: 1,150,000 shares worth $115M.
  • Avidity Partners Management added most to Avantor in Q4 2020, an estimated $51.7M increase.
  • Avidity Partners Management's biggest Q4 2020 reduction was Biohaven Pharmaceutical Holding Company Ltd., cutting an estimated $67.1M.
  • Avidity Partners Management fully exited Seagen Inc. Common Stock in Q4 2020, selling an estimated $104M.
  • Avidity Partners Management's ten largest holdings make up 38% of its $3.08B portfolio in Q4 2020.
  • Avidity Partners Management opened 53 new positions and closed 25 in Q4 2020.
  • Avidity Partners Management's portfolio value rose 43% quarter-over-quarter to $3.08B.

Based on Avidity Partners Management's 13F filing for Q4 2020, filed 16 Feb 2021.